



Curriculum Vitae

Personal information **Marja van de Bovenkamp**

Work experience

1. Employer: Medicines Evaluation Board
 - Start date: 2011
 - End date:
 - Position: Assessor
 - Activities: Quality assessment of biological medicines, with focus on ATMPs and plasma-derived products
 - Country: Netherlands
2. Employer: Governmental Institute for Public Health and the Environment, Centre for Biologicals and Medical Technology
 - Start date: 2010
 - End date: 2011
 - Position: Assessor
 - Activities: Quality assessment of biological medicines
 - Country: Netherlands
3. Employer: Governmental Institute for Public Health and the Environment, Centre for Substances and Integrated Risk Assessment
 - Start date: 2007
 - End date: 2010
 - Position: Assessor
 - Activities: Risk assessment human toxicology
 - Country: Netherlands
4. Employer: University of Ottawa
 - Start date: 2006
 - End date: 2007
 - Position: Postdoctoral Research Fellow
 - Activities: Research on breast cancer genes
 - Country: Canada

Education and training

1. Subject: In vitro models for liver fibrosis
 - Start date: 2002
 - End date: 2006
 - Qualification: PhD
 - Organisation: University of Groningen
 - Country: Netherlands
2. Subject: Biomedical sciences
 - Start date: 1996
 - End date: 2001
 - Qualification: M.Sc.
 - Organisation: University of Utrecht
 - Country: Netherlands

Additional information

Publications

- De Wolf C, Van de Bovenkamp M, Hoefnagel M. Regulatory perspective on in vitro potency assays for human dendritic cells used in anti_tumor immunotherapy. *Cytotherapy*. 2018 Nov;20(11):1289_1308.
- De Wolf C, Van de Bovenkamp M, Hoefnagel M. Regulatory perspective on in vitro potency assays for human T cells used in anti_tumor immunotherapy. *Cytotherapy*. 2018 May;20(5):601_622.
- De Wolf C, Van de Bovenkamp M, Hoefnagel M. Regulatory perspective on in vitro potency assays for human mesenchymal stromal cells used in immunotherapy. *Cytotherapy*. 2017 Jul;19(7):784_797.
- Marquart H, Meijster T, Van de Bovenkamp M, Ter Burg W, Spaan S, Van Engelen J A structured approach to Exposure Based Waiving of human health endpoints under REACH developed in the OSIRIS project *Regulatory Toxicology and Pharmacology* 62(2): 231_40, 2012
- Vermeire TG, Van de Bovenkamp M, Bruinen de Bruin Y, Delmaar C, Van Engelen JGM, Escher S, Marquart H, Meijster T Exposure_based waiving under REACH *Regulatory Toxicology and Pharmacology* 58(3): 408_20, 2010
- Van de Bovenkamp M, Jeurissen SMF, Pelgrom SMGJ, Spijkerboer HN, Van Riel AJHP, De Kaste D, Baars AJ, Pronk MEJ. Beoordeling van de gezondheidsrisico's van 'verboden kruiden' [Evaluation of the health risks associated with so_called banned herbs] RIVM_report 320011002, 2009
- Vermeire TG, Bessems JGM, Van de Bovenkamp M, Dang Z, Van Engelen JGM, Gunnarsdottir S, Hagens WI, Links I, Marquart H, Mikkers J, Van Zijverden M Exposure informed testing under REACH RIVM_report 601017001, 2008
- Van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P Liver slices as a model to study fibrogenesis and test the effects of anti_fibrotic drugs on fibrogenic cells in human liver. *Toxicology in Vitro* 22(3):771_8, 2008

Van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P Liver fibrosis in vitro: cell culture models and precision_cut liver slices. (Review) *Toxicology in Vitro* 21(4):545_57, 2007

Gonzalo T, Beljaars L, Van de Bovenkamp M, Temming K, van Loenen AM, Reker_Smit C, Meijer DKF, Lacombe M, Opdam F, Keri G, Orfi L, Poelstra K, Kok RJ Local inhibition of liver fibrosis by specific delivery of a PDGF kinase inhibitor to hepatic stellate cells. *Journal of Pharmacology and Experimental Therapeutics* 321(3):856_65 2007

Van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P Precision_cut fibrotic rat liver slices as a new model to test anti_fibrotic drugs *Journal of Hepatology* 45: 696_703, 2006

Van de Bovenkamp M, Groothuis GMM, Meijer DKF, Olinga P Human liver slices as an in vitro model to study toxicity_induced hepatic stellate cell activation in a multi_cellular milieu *Chemico_Biological Interactions* 162: 62_69, 2006

Van de Bovenkamp M, Groothuis GMM, Draaisma AL, Merema MT, Bezuijen JI, Van Gils MJ, Meijer DKF, Friedman SL, Olinga P Precision_cut liver slices as a new model to study toxicity_induced hepatic stellate cell activation in a physiologic milieu *Toxicological Sciences* 85: 632_638, 2005

Van de Bovenkamp, M Liver fibrosis in vitro: Liver slices as a promising alternative (Thesis) Online publication: <http://irs.uu.nl/ppn/297065254>

Pereira CF, Paridaen JTML, Van de Bovenkamp M, Middel J, Verhoef J, Nottet HSLM APHS can act synergically with clinically available HIV_I reverse transcriptase and protease inhibitors and is active against several drug_resistant HIV_I strains in vitro *Journal of Antimicrobial Chemotherapy* 51: 1181_1189, 2003

Pereira CF, Paridaen JTML, Rutten K, Huigen MCDG, Van de Bovenkamp M, Middel J, Verhoef J, Nottet HSLM Aspirin_like molecules that inhibit human immunodeficiency virus_I replication *Antiviral Research* 58: 253_263, 2003

Van de Bovenkamp M, Nottet HSLM, Pereira CF Interactions of human immunodeficiency virus_I proteins with neurons: possible role in the development of human immunodeficiency virus_I associated dementia (Review) *European Journal of Clinical Investigation* 32: 619_627, 2002

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)